ALLAN LARCENA: Open Payments
NPI 1275579724 · SLIDELL, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,363 in 63 payments from 14 companies in 2025. Trend: 2023 $2,093 · 2024 $2,145 · 2025 $1,363
Food & beverage: $1,363
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 25 | $651 |
| GlaxoSmithKline, LLC. | 13 | $243 |
| Lilly USA, LLC | 3 | $60 |
| Novartis Pharmaceuticals Corporation | 3 | $60 |
| Exact Sciences Corporation | 3 | $57 |
| Amgen Inc. | 3 | $48 |
| Lundbeck LLC | 2 | $45 |
| ABBVIE INC. | 2 | $39 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $36 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $34 |
Products named: BREZTRI, TRELEGY ELLIPTA, FARXIGA, JARDIANCE, LEQVIO, OTEZLA, REXULTI, AIRSUPRA.
Industry payments across LA — which companies pay providers there.
